PINNED
PINNED
Endotoxin testing milestone reached with European Pharmacopoeia’s animal shift
The quality control (QC) standards publication sets animal-free bacterial endotoxins testing (BET) as the new norm in Europe.
List view / Grid view
News
Oxbryta® significantly improves haemoglobin levels in paediatric sickle cell disease patients
Data shows treating sickle cell disease patients aged four to 11 years with Oxbryta® (voxelotor) results in increases in haemoglobin associated with improved clinical status.
Janssen COVID-19 Vaccine – one regulator blocks use, another promotes it
EU recommends that batches of Janssen COVID-19 Vaccine not be released for use due to a cross contamination report, while the FDA authorises use of drug substance from the facility where the contamination occurred.
Comirnaty® COVID-19 vaccine protects against multiple viral variants
Laboratory study shows the blood sera of people vaccinated against COVID-19 with Comirnaty® can neutralise at least six viral variants including three variants of concern.
US National Institutes of Health commits to ending racism in biomedical science
Scientists, administrators, staff and leaders at the NIH have laid out their framework under the UNITE initiative to end structural racism in the biomedical industry.
COVID-19 antibody therapies safe and effective for transplant patients
Monoclonal antibody therapies found to reduce progression to severe disease, risk of hospitalisation and death in transplant recipients with mild to moderate COVID-19.
DFE pharma joins UK’s leading initiative for innovation in drug manufacturing
DFE Pharma is the latest member of the UK’s Medicines Manufacturing Innovation Centre and will work on Grand Challenge 1: improving the manufacture of oral solid dosage medicines.
Janssen COVID-19 Vaccine can protect against variants of concern
Trial shows the single-shot Janssen COVID-19 Vaccine generates robust immune responses against several COVID-19 variants.
Cancer vaccine shows promise in glioblastoma trial
Personalised cancer vaccine increases progression free survival by approximately 50 percent in patients with newly diagnosed glioblastoma.
Sanaria® PfSPZ-CVac vaccine 75 percent effective at preventing malaria
Clinical studies optimising immunisation with Sanaria’s PfSPZ-CVac vaccine resulted in 77 and 75 percent of participants being protected from malaria infection.
Novel microfluidic device could enhance crystalline drug safety
The continuous-flow microfluidic device allows scientists to assess crystalline API growth rates, shapes and structures to more quickly identify the best conditions for drug manufacturing.
EMA to assess whether COVID-19 Vaccine Moderna can be used in adolescents
The European Medicines Agency (EMA) has begun evaluating whether to extend the use of the COVID-19 Vaccine Moderna to include adolescents aged 12 to 17.
Experts call for improved oversight to combat rise of unproven stem cell therapies
Stem cell therapy authorities urge the WHO to create an advisory committee for regenerative medicine and work to combat the rising use of unproven stem cell therapies worldwide.
Alzheimer’s drug Aduhelm™ authorised in US under accelerated approval
Aduhelm™ (aducanumab-avwa) is the first new treatment approved for Alzheimer’s since 2003 and the first therapy to target the fundamental pathophysiology of the disease – amyloid plaques.
Imfinzi increases five year survival to 43 percent in Stage III lung cancer trial
New data shows AstraZeneca’s Imfinzi (durvalumab) achieved an unprecedented five year survival rate of over 40 percent in patients with Stage III non-small cell lung cancer.
![MIT chemical engineers have devised a new way to formulate hydrophobic drugs by turning them into a nanoemulsion, which can be poured into a mold and dried into tablets. The nanoemulsion can also be used to form small particles, seen in the vials [Credit: Felice Frankel].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/MIT-HYDROPHOBIC-DRUGS-nanoemulsion-300x278.jpg)
![MIT chemical engineers have devised a new way to formulate hydrophobic drugs by turning them into a nanoemulsion, which can be poured into a mold and dried into tablets. The nanoemulsion can also be used to form small particles, seen in the vials [Credit: Felice Frankel].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/MIT-HYDROPHOBIC-DRUGS-nanoemulsion-e1623151984970.jpg)
Thermogelling nanoemulsion enhances drug loading of hydrophobic APIs
Using a new formulation technique, researchers were able to more than double drug loading of a hydrophobic active pharmaceutical ingredient in tablets. Thus, the new formulation method may lead to smaller pills delivering the same therapeutic benefit.
